Notable News to Watch: Immunomedics (NASDAQ:IMMU)

On Friday, Immunomedics (NASDAQ:IMMU) started its trading session with the price $20.7 and closed at price of $20.67 by scoring -0.29%. Day range of the stock was $20.62 – $21.37. IMMU stock traded with total volume of 1615861 shares while the average trading capacity remained 2354189 shares.  Earnings per share was $-1.51. IMMU has total market capitalization of $4327574565.

On Dec. 09, 2019, Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), notified the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 16,428,572, composed of 14,285,715 shares of common stock initially offered and an additional 2,142,857 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $17.50 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.

Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.

Cheyenne Cox is a news report covering multiple Market and economy News. She is creative and highly professional writer. Cheyenne holds a degree in communication and journalism and has also a Diploma in digital marketing. She belongs to south Africa who has also lived in Europe and is currently based in the US.

Leave a Reply

Your email address will not be published. Required fields are marked *